Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Hybrid graphene oxide as carrier of doxorubicin: cytotoxicity and preliminary in vivo assays against bladder cancer

Full text
Author(s):
Favaro, Wagner J. [1] ; de Souza, Joel G. [1] ; Ferreira, Luiz A. B. [2] ; de Jesus, Marcelo B. [2] ; Duran, Marcela [1] ; Bockelmann, Petra K. [1] ; Bernardes, Juliana S. [3] ; Duran, Nelson [1, 4]
Total Authors: 8
Affiliation:
[1] Univ Estadual Campinas, Dept Struct & Funct Biol, Lab Urogenital Carcinogenesis & Immunotherapy, Campinas, SP - Brazil
[2] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP - Brazil
[3] Brazilian Ctr Res Energy & Mat CNPEM, Brazilian Nanotechnol Natl Lab LNNano, Campinas, SP - Brazil
[4] Fed Univ ABC UFABC, Nanomed Res Unit NANOMED, Santo Andre, SP - Brazil
Total Affiliations: 4
Document type: Journal article
Source: ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY; v. 11, n. 2 JUN 2020.
Web of Science Citations: 0
Abstract

Two types of graphene oxide (GO) hybrids were synthesised for the administration of doxorubicin (DOX, named GO-CO-DOX) and interfering RNA - siRNA (named GO-PEG-PEI/siRNA). These nanomaterials were used for intervention on vascular endothelial growth factor (VEGF) that represents an important strategy to block the formation of new vessels to inhibit cancer progression. For the delivery of DOX, it was incorporated into GO, while for the delivery of siRNA, GO was covalently bonded with the cationic polyethyleneimine (PEI) and then complexed with siRNA. The nanostructures were characterised by attenuated total reflection ATR-FTIR, zeta potential, x-ray photoelectron spectroscopy (XPS), x-ray diffraction (XRD), and transmission electron microscopy (TEM). The cytotoxicity studies with GO-PEG-PEI and GO-PEG-PEI/siRNA systems showed that both formulations have IC50 values of around 100 mu g ml(-1). The systems were administered in vivo to investigate their antitumor effects against non-muscle-invasive bladder cancer (NMIBC) and showed to be promising for the treatment of NMIBC. (AU)

FAPESP's process: 14/11154-1 - Development of graphene oxide hybrids as platform for the treatment of non-invasive bladder cancer: interactions of Bacillus Calmette-Gueri immunotherapy, metformin and RNA interference
Grantee:Joel Gonçalves de Souza
Support Opportunities: Scholarships in Brazil - Post-Doctoral